Davor Hrabar1, Petra Cacic2, Alen Biscanin2, Vedran Tomasic2, Dominik Kralj2, Doris Ogresta2, Stipe Pelajic2, Zdravko Dorosulic2, Toni Babarovic3. 1. Department of Gastroenterology and Hepatology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia. 2. Department of Gastroenterology and Hepatology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia. 3. Institute of Social Sciences Ivo Pilar, Zagreb, Croatia.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 pandemic is affecting public health systems and mental health significantly. Patients with inflammatory bowel disease are witnessing vigorous organizational changes in inflammatory bowel disease centers and experiencing all psychosocial effects of the crisis. We conducted a single-center cross-sectional study in order to assess inflammatory bowel disease patients' concerns, behavior, and satisfaction with provided healthcare during severe acute respiratory syndrome coronavirus 2 pandemic. METHODS: All inflammatory bowel disease patients treated in our center from April 1 to June 1, 2020, were invited to fulfill an anonymous online questionnaire. RESULTS: A total of 132 participants have completed the questionnaire, 63.2% were female, 57.9% had Crohn's disease (CD) During the first wave of the pandemic, 74.2% of participants perceived themselves as a high-risk group for acquiring coronavirus disease 2019 only because they suffered from inflammatory bowel disease, and 66.2% thought inflammatory bowel disease medications make them more susceptible to coronavirus disease 2019. This especially concerned patients treated with biologics (B = 2.068, P < .01). Females were more stressed (B = -1.451, P < .01) and concerned (B = -1.488, P < .01) about the pandemic, and they also reported more potential benefits from professional psychological help (B = -2.664, P = .02). Six patients (5.3%) discontinued inflammatory bowel disease therapy on their own initiative. Seventy-eight (68.4%) patients were completely satisfied and 14 (12.3%) were partially satisfied with the quality of healthcare provided in our inflammatory bowel disease center. CONCLUSION: Female inflammatory bowel disease patients tend to be more emotionally vulnerable during severe acute respiratory syndrome coronavirus 2 pandemic. Although psychological support should be continuously available to all inflammatory bowel disease patients, female gender may warrant special attention. Providing patients with adequate and early information during pandemic probably leads to better compliance and higher satisfaction.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 pandemic is affecting public health systems and mental health significantly. Patients with inflammatory bowel disease are witnessing vigorous organizational changes in inflammatory bowel disease centers and experiencing all psychosocial effects of the crisis. We conducted a single-center cross-sectional study in order to assess inflammatory bowel disease patients' concerns, behavior, and satisfaction with provided healthcare during severe acute respiratory syndrome coronavirus 2 pandemic. METHODS: All inflammatory bowel disease patients treated in our center from April 1 to June 1, 2020, were invited to fulfill an anonymous online questionnaire. RESULTS: A total of 132 participants have completed the questionnaire, 63.2% were female, 57.9% had Crohn's disease (CD) During the first wave of the pandemic, 74.2% of participants perceived themselves as a high-risk group for acquiring coronavirus disease 2019 only because they suffered from inflammatory bowel disease, and 66.2% thought inflammatory bowel disease medications make them more susceptible to coronavirus disease 2019. This especially concerned patients treated with biologics (B = 2.068, P < .01). Females were more stressed (B = -1.451, P < .01) and concerned (B = -1.488, P < .01) about the pandemic, and they also reported more potential benefits from professional psychological help (B = -2.664, P = .02). Six patients (5.3%) discontinued inflammatory bowel disease therapy on their own initiative. Seventy-eight (68.4%) patients were completely satisfied and 14 (12.3%) were partially satisfied with the quality of healthcare provided in our inflammatory bowel disease center. CONCLUSION: Female inflammatory bowel disease patients tend to be more emotionally vulnerable during severe acute respiratory syndrome coronavirus 2 pandemic. Although psychological support should be continuously available to all inflammatory bowel disease patients, female gender may warrant special attention. Providing patients with adequate and early information during pandemic probably leads to better compliance and higher satisfaction.
Authors: Antonina A Mikocka-Walus; Deborah A Turnbull; Nicole T Moulding; Ian G Wilson; Jane M Andrews; Gerald J Holtmann Journal: Inflamm Bowel Dis Date: 2007-02 Impact factor: 5.325
Authors: A N Ananthakrishnan; V S Gainer; R G Perez; T Cai; S-C Cheng; G Savova; P Chen; P Szolovits; Z Xia; P L De Jager; S Y Shaw; S Churchill; E W Karlson; I Kohane; R H Perlis; R M Plenge; S N Murphy; K P Liao Journal: Aliment Pharmacol Ther Date: 2013-01-07 Impact factor: 8.171
Authors: John R Walker; Jason P Ediger; Lesley A Graff; Jay M Greenfeld; Ian Clara; Lisa Lix; Patricia Rawsthorne; Norine Miller; Linda Rogala; Cory M McPhail; Charles N Bernstein Journal: Am J Gastroenterol Date: 2008-08 Impact factor: 10.864
Authors: Eduardo Martin Arranz; Cristina Suarez Ferrer; Laura García Ramírez; Jose Luis Rueda García; María Sánchez-Azofra; Joaquín Poza Cordón; Jesus Noci; Yamile Zabana; Manuel Barreiro-de Acosta; María Dolores Martín-Arranz Journal: Inflamm Bowel Dis Date: 2020-07-17 Impact factor: 5.325
Authors: Jennie N Clough; Katie L Hill; Alexa Duff; Esha Sharma; Shuvra Ray; Joel E Mawdsley; Simon Anderson; Peter M Irving; Mark A Samaan Journal: Inflamm Bowel Dis Date: 2020-09-18 Impact factor: 5.325
Authors: Samantha K Brooks; Rebecca K Webster; Louise E Smith; Lisa Woodland; Simon Wessely; Neil Greenberg; Gideon James Rubin Journal: Lancet Date: 2020-02-26 Impact factor: 79.321